Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients

Regulatory information
An initial evaluation of the ongoing US study with IdeS at Cedars Sinai Medical Center shows that IdeS completely eliminates donor specific antibodies and allows for kidney transplantation in all sensitized patients. These results are for four patients that were included in the US study as of January 2016. As of today 10 patients have been treated and subsequently transplanted. Initial results from the study will be presented by Professor Stanley Jordan, the study’s principal investigator, at the 2016 American Transplant Congress (ATC) in Boston on June 14 at 6:00 pm.

The ongoing Phase II study at Cedars Sinai Medical Center is an investigator-initiated study that is looking at the effects of IdeS in enabling kidney transplantation in highly sensitized kidney transplant patients. The study will eventually recruit up to 20 patients and of today a total of 10 patients have been treated and subsequently transplanted.

The conclusion from the initial evaluation is that IdeS treatment of highly sensitized (HS) patients completely eliminates donor specific antibodies (DSAs) present at transplant and allows for successful transplantation of HLA incompatible patients. IdeS is well tolerated without infusion-related side effects and no significant infections to date.  IdeS may provide a rapid, effective and durable method to eliminate DSAs and transplant HS patients who are resistant to current desensitization (DES).

Professor Stanley Jordan will present data from all included patients in this study at the American Transplant Congress in Boston. A meeting abstract, including the first four patients, has been published ahead of the presentation at the ATC website:

http://www.atcmeetingabstracts.com/abstract/initial-experience-with-the-bacterial-enzyme-ides-igg-endopeptidase-for-desensitization-of-highly-hla-sensitized-hs-patients/

The information in this press release is disclosed pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for public disclosure on May 17, 2016 at 08.30 CET.